All In MedTech

Device Trial Radar · NCT05318417

Investigation to Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-sided Deafness

A Post-approval, Prospective, Nonrandomized, Single-arm Multicenter Investigation to Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-sided Deafness

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 19, 2022

Primary completion

May 2027

Study completion Jun 2027

Sponsor

Lead sponsor
CochlearNot on our public-company list
Sponsor type
Industry
Collaborators
NAMSA
First posted
Apr 8, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to assess the continued efficacy and safety of cochlear implantation in participants aged 5 years and above with Unilateral Hearing Loss (UHL)/Single Sided Deafness (SSD) supporting a change indication for use.

Conditions

  • Hearing Loss, Unilateral
  • Deafness, Unilateral

Interventions

  • The Cochlear™ Nucleus® Cochlear Implant (CI) SystemDevice

    The Cochlear™ Nucleus® CI systems are designed to provide useful hearing. The system works by converting sound in the environment into electric pulses that stimulate the auditory nerve, allowing the brain to perceive sound. The Cochlear™ Nucleus® CI system has implanted and external components. Implanted component: The CI is surgically implanted under the skin behind the ear. It includes a receiver/stimulator to receive and decode the electrical signals from the sound processor and an electrode to deliver these signals to the cochlear. External components: The external components include a sound processor, and associated accessories and cables. The system is programmed by a Cochlear proprietary programming system, Custom Sound®.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in sentence in noise scores at 12 months post-activation in the binaural (CI and normal hearing (NH)) listening condition compared to preoperatively in the best listening (NH alone or NH and hearing aid) condition in 3 speaker configurations.Time frame: pre-implantation, 12 months post-activation
  2. Number of procedure and device related adverse events classified by type, frequency and severity.Time frame: 36 months post-activation

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

  • Rocky Mountain Ear Center

    Englewood, Colorado

  • University of Iowa

    Iowa City, Iowa

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.